371 related articles for article (PubMed ID: 34511320)
41. Clinical Outcomes in Patients with Multi-Hit
Brieghel C; Aarup K; Torp MH; Andersen MA; Yde CW; Tian X; Wiestner A; Ahn IE; Niemann CU
Clin Cancer Res; 2021 Aug; 27(16):4531-4538. PubMed ID: 33963002
[TBL] [Abstract][Full Text] [Related]
42. Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany.
Hoechstetter MA; Knauf W; Dambacher S; Hucke N; Höhne K; van Troostenburg A; Ramroth H; Abenhardt W; Rummel M
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e777-e787. PubMed ID: 35624058
[TBL] [Abstract][Full Text] [Related]
43. Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Cramer P; Tresckow JV; Robrecht S; Bahlo J; Fürstenau M; Langerbeins P; Pflug N; Al-Sawaf O; Heinz WJ; Vehling-Kaiser U; Dürig J; Tausch E; Hensel M; Sasse S; Fink AM; Fischer K; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
Haematologica; 2021 Feb; 106(2):543-554. PubMed ID: 32107341
[TBL] [Abstract][Full Text] [Related]
44. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
45. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
Ahn IE; Farooqui MZH; Tian X; Valdez J; Sun C; Soto S; Lotter J; Housel S; Stetler-Stevenson M; Yuan CM; Maric I; Calvo KR; Nierman P; Hughes TE; Saba NS; Marti GE; Pittaluga S; Herman SEM; Niemann CU; Pedersen LB; Geisler CH; Childs R; Aue G; Wiestner A
Blood; 2018 May; 131(21):2357-2366. PubMed ID: 29483101
[TBL] [Abstract][Full Text] [Related]
46. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke.
Narezkina A; Akhter N; Lu X; Emond B; Panjabi S; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Choi M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e959-e971. PubMed ID: 35973891
[TBL] [Abstract][Full Text] [Related]
47. [Ibrutinib: A new drug of B-cell malignancies].
Thieblemont C
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
[TBL] [Abstract][Full Text] [Related]
48. Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
Stephens DM; Huang Y; Ruppert AS; Walker JS; Canfield D; Cempre CB; Fu Q; Baker S; Hu B; Shah H; Vadeboncoeur R; Rogers KA; Bhat S; Jaglowski SM; Lockman H; Lapalombella R; Byrd JC; Woyach JA
Clin Cancer Res; 2022 Aug; 28(15):3242-3247. PubMed ID: 35608822
[TBL] [Abstract][Full Text] [Related]
49. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
[TBL] [Abstract][Full Text] [Related]
50. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
Molica S
Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
[TBL] [Abstract][Full Text] [Related]
51. Use of Ibrutinib in 10 Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Real-World Clinical Practice -A Report from a Single Medical Institution.
Sekiguchi Y; Iizuka H; Takizawa H; Mitsumori T; Tomita S; Izumi H; Okubo M; Miyake K; Osawa T; Sawada T; Yoshikawa S; Noguchi M
Gan To Kagaku Ryoho; 2021 Jul; 48(7):921-926. PubMed ID: 34267029
[TBL] [Abstract][Full Text] [Related]
52. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.
Stephens DM; Byrd JC
Blood; 2019 Mar; 133(12):1298-1307. PubMed ID: 30642919
[TBL] [Abstract][Full Text] [Related]
53. Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.
Deeks ED
Drugs; 2017 Feb; 77(2):225-236. PubMed ID: 28105602
[TBL] [Abstract][Full Text] [Related]
54. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.
Kittai AS; Miller C; Goldstein D; Huang Y; Abruzzo LV; Beckwith K; Bhat SA; Bond DA; Grever MR; Heerema NA; Rogers KA; Ruppert AS; Byrd JC; Woyach JA
Blood; 2021 Dec; 138(23):2372-2382. PubMed ID: 34314481
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data.
Tombak A; Pepedil Tanrıkulu F; Durusoy SS; Dinçyürek HD; Kaya E; Ümit EG; Yavaşoğlu İ; Mehtap Ö; Deveci B; Özcan MA; Terzi H; Okay M; Sayınalp N; Yılmaz M; Okan V; Kızıklı A; Özcan Ö; Çetin G; Demircioğlu S; Aydoğdu İ; Saydam G; Davulcu EA; İlhan G; Uçar MA; Özet G; Akpınar S; Turgut B; Berber İ; Kurtoğlu E; Sönmez M; Batur DS; Yıldırım R; Özkocamaz V; Güneş AK; Sahip B; Ertop Ş; Akay OM; Baştürk A; Doğu MH; Akdeniz A; Ünal A; Seyhanlı A; Gürkan E; Çekdemir D; Ferhanoğlu B
Turk J Haematol; 2021 Dec; 38(4):273-285. PubMed ID: 34448556
[TBL] [Abstract][Full Text] [Related]
56. Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.
Barrientos JC; Ayed AO; Cha A; Du S; Fang B; Hall R; Marks SM; Peng E; Rhodes JM; Ryan K; Winters SB; Yeung PL; Hou JZ
Target Oncol; 2023 Sep; 18(5):727-734. PubMed ID: 37728835
[TBL] [Abstract][Full Text] [Related]
57. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.
Jacobs R; Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Levy MY
Future Oncol; 2024 Jan; 20(1):39-53. PubMed ID: 37476983
[TBL] [Abstract][Full Text] [Related]
58. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.
Allan JN; Flinn IW; Siddiqi T; Ghia P; Tam CS; Kipps TJ; Barr PM; Elinder Camburn A; Tedeschi A; Badoux XC; Jacobs R; Kuss BJ; Trentin L; Zhou C; Szoke A; Abbazio C; Wierda WG
Clin Cancer Res; 2023 Jul; 29(14):2593-2601. PubMed ID: 37282671
[TBL] [Abstract][Full Text] [Related]
59. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
Liu W; Burger JA; Xu J; Tang Z; Toruner G; Khanlari M; Medeiros LJ; Tang G
Ann Hematol; 2020 Oct; 99(10):2343-2349. PubMed ID: 32833105
[TBL] [Abstract][Full Text] [Related]
60. Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry.
Mato AR; Barrientos JC; Ghosh N; Pagel JM; Brander DM; Gutierrez M; Kadish K; Tomlinson B; Iyengar R; Ipe D; Upasani S; Amaya-Chanaga CI; Sundaram M; Han J; Giafis N; Sharman JP
Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):174-183.e3. PubMed ID: 32033927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
